IPO for ProLung, Inc.
We are a medical technology company specializing in predictive analytic, early stage lung cancer risk testing, which we refer to as the “ProLung Test.” Our noninvasive, painless and radiation-free ProLung Test was developed to rapidly assess the risk of malignancy in lung nodules found in the chest by a Computed Tomography (“CT”) scan, which is currently the primary method used for the early detection of lung cancer. As lung cancer is the leading cause of cancer death, early detection makes a substantial improvement in survival in a large population group. Timely identi?cation of malignancy is essential for patients and their families. Currently, patients often wait from three months to three and one-half years to have the risk of malignancy assessed through periodic CT scan surveillance. Until malignancy is determined to be likely, invasive biopsy and treatment are signi?cantly delayed. Current statistics re?ect a 17% survival rate at ?ve years for those diagnosed with lung cancer.Show More
Key IPO Data
How Does an IPO Work?
Open a Motif Account
Open a brokerage account to get ready for trading.
Participate in an IPO
Review IPO pricing, prospectus, and other documentation.
Place a Conditional Order
Select an investment amount and fund the IPO.